- Public Comps
- 4basebio
4basebio Valuation Multiples
Discover revenue and EBITDA valuation multiples for 4basebio and similar public comparables like Bioventix, ArcticZymes, SDI Group, Curiosis and more.
4basebio Overview
About 4basebio
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.
Founded
2019
HQ

Employees
110
Website
Financials (LTM)
EV
$108M
Valuation Multiples
Start free trial4basebio Financials
4basebio reported last 12-month revenue of $3M and negative EBITDA of ($21M).
In the same LTM period, 4basebio generated $2M in gross profit, ($21M) in EBITDA losses, and had net loss of ($22M).
4basebio P&L
In the most recent fiscal year, 4basebio reported revenue of $2M and EBITDA of ($21M).
4basebio is unprofitable as of last fiscal year, with gross margin of 58%, EBITDA margin of (920%), and net margin of (997%).
Financial data powered by Morningstar, Inc.
4basebio Stock Performance
4basebio has current market cap of $109M, and enterprise value of $108M.
Market Cap Evolution
4basebio's stock price is $7.06.
4basebio share price increased by 2.5% in the last 30 days, and decreased by 45.5% in the last year.
4basebio has an EPS (earnings per share) of $-1.47.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $108M | $109M | -0.2% | 2.5% | 3.7% | -45.5% | $-1.47 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free Trial4basebio Valuation Multiples
4basebio trades at 34.9x EV/Revenue multiple, and (5.2x) EV/EBITDA.
4basebio Financial Valuation Multiples
As of July 19, 2026, 4basebio has market cap of $109M and EV of $108M.
4basebio has a P/E ratio of (4.9x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified 4basebio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


4basebio Margins & Growth Rates
4basebio grew revenue by 65% but EBITDA decreased by 6% in the last fiscal year.
In the most recent fiscal year, 4basebio reported gross margin of 58%, EBITDA margin of (920%), and net margin of (997%).
4basebio Margins
4basebio Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
4basebio Operational KPIs
4basebio's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.
4basebio's Rule of 40 is (456%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
4basebio's Rule of X is (358%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
4basebio Competitors
4basebio competitors include Bioventix, ArcticZymes, SDI Group, Curiosis, HAEMATO, Vitrafy, Jagsonpal Pharma, Insight Molecular, Diaceutics and iNtRON Biotechnology.
Most 4basebio public comparables operate across Life Sciences Tools, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 5.8x | - | 7.4x | - | |||
| 6.1x | 5.6x | 33.5x | 38.3x | |||
| 1.8x | 1.5x | 9.7x | 8.0x | |||
| 26.7x | 16.2x | (29.3x) | (64.4x) | |||
| 0.2x | - | 3.1x | - | |||
| 2932.0x | 93.1x | (15.0x) | (10.9x) | |||
| 4.8x | - | 20.3x | - | |||
| 31.5x | 42.5x | (4.9x) | (4.6x) | |||
This data is available for Pro users. Sign up to see all 4basebio competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout 4basebio
| When was 4basebio founded? | 4basebio was founded in 2019. |
| Where is 4basebio headquartered? | 4basebio is headquartered in United Kingdom. |
| How many employees does 4basebio have? | As of today, 4basebio has over 110 employees. |
| Who is the CEO of 4basebio? | 4basebio's CEO is Amy Jo Walker. |
| Is 4basebio publicly listed? | Yes, 4basebio is a public company listed on London Stock Exchange. |
| What is the stock symbol of 4basebio? | 4basebio trades under 4BB ticker. |
| When did 4basebio go public? | 4basebio went public in 2021. |
| Who are competitors of 4basebio? | 4basebio main competitors include Bioventix, ArcticZymes, SDI Group, Curiosis, HAEMATO, Vitrafy, Jagsonpal Pharma, Insight Molecular, Diaceutics, iNtRON Biotechnology. |
| What is the current market cap of 4basebio? | 4basebio's current market cap is $109M. |
| What is the current revenue of 4basebio? | 4basebio's last 12 months revenue is $3M. |
| What is the current revenue growth of 4basebio? | 4basebio revenue growth (NTM/LTM) is 241%. |
| What is the current EV/Revenue multiple of 4basebio? | Current revenue multiple of 4basebio is 34.9x. |
| Is 4basebio profitable? | No, 4basebio is not profitable. |
| What is the current EBITDA of 4basebio? | 4basebio has negative EBITDA and is not profitable. |
| What is 4basebio's EBITDA margin? | 4basebio's last 12 months EBITDA margin is (674%). |
| What is the current EV/EBITDA multiple of 4basebio? | Current EBITDA multiple of 4basebio is (5.2x). |
| What is the current FCF of 4basebio? | 4basebio's last 12 months FCF is ($22M). |
| What is 4basebio's FCF margin? | 4basebio's last 12 months FCF margin is (704%). |
| What is the current EV/FCF multiple of 4basebio? | Current FCF multiple of 4basebio is (5.0x). |
| How many companies 4basebio has acquired to date? | 4basebio hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies 4basebio has invested to date? | 4basebio hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to 4basebio
Lists including 4basebio
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




